Cultivation Capital’s Life Sciences Fund II invests in early-stage life sciences companies, primarily in the therapeutics, diagnostics, research tools and reagents, medical devices, and healthcare information technology verticals.

Our sweet spot is providing post-seed/pre-Series A stage companies the capital they need to rapidly scale their businesses. Our initial investment ranges from $250,000 – $1,000,000, with opportunities for follow-on investment.

Our partners are seasoned entrepreneurs turned investors, who know what it takes to grow and successfully exit a life sciences business. Drawing upon their expertise, we actively support our portfolio companies, many times serving as a lead investor and board member.

Bill

Bill Schmidt
Managing Partner

Dean

Dean Vandekamp
General Partner

rickryan

Rick Ryan
General Partner

david

David Smoller
General Partner

Rick Holton Jr.
Co-Founder & General Partner

cdanforth

Chris Danforth
General Partner

Bobby Sandage Site

Bobby Sandage
General Partner

null

Adarza Biosystems develops and manufacturers a new multiplex immunoassay technology that can quickly identify proteins and genetic markers in medical specimens.

null

ARVEGENIX is developing and genetically improving Field Pennycress as an oilseed crop that will produce high-quality oil for industrial and renewable fuels.

null

Benson Hill Biosystems is an agricultural solutions company that unlocks the global genetic potential of plants to enhance fuel production.

null

BlueStrata EHR is a Software as a Service model EHR software platform developed for the Long Term Care industry that integrates care services.

null

Cardialen, a medical company revolutionizing atrial fibrillation (AF) treatment by developing gentle low-voltage pulses released from a small implantable device.

null

Euclises Pharmaceuticals, Inc is developing novel pain and cancer medications that offer superior safety margins compared to existing drugs.

null

Galera Therapeutics is a clinical-stage biotech company focused on the development of breakthrough drugs targeting the oxygen metabolic pathways.

null

Immunophotonics is a biotechnology company engaged developing a proprietary novel drug product for use in an in situ autologous cancer vaccine.

null

Mobius Therapeutics aims to correct this imbalance and provide new hope to the tens of thousands of glaucoma patients surgically treated each year.

null

Molecular Sensing is the world’s first label-free, conformation-sensitive, free-solution assay technology for biophysical characterization.

null

Pulse Therapeutics focuses on developing an innovative approach to supporting the delivery of treatment of acute ischemic stroke.

null

Sequoia’s UTI vaccine consists of a bacterial adhesin protein that is essential for the recurrence of UTIs, and a new adjuvant.

null

Tioma Theraputics. focuses on the development of proprietary drugs for life-threatening disorders driven by CD47-mediated signaling pathways.

null

VENITI is a medical device company developing innovative technology and solutions that will provide treatment across the venous disease continuum.